The UK and US have signed a significant commercial pact that will guarantee no import taxes on UK pharmaceutical shipments being sold in the US market.
Key Provisions of the Accord
As part of the deal, the UK has committed to boost spending on pharmaceuticals through the public health system. This move secures that duties on these vital products will stay at zero for a timeframe of three years.
This agreement comes after recent warnings to significantly raise tariffs on branded pharmaceutical products, with figures floated as high as 100%.
"This arrangement with the Britain reinforces the international landscape for innovative medicines and introduces long-overdue fairness to transatlantic pharmaceutical trade," an announcement declared.
Trade Significance
Pharmaceuticals are one of the the United Kingdom's most significant export categories to the America, which is easily the primary market for major British pharmaceutical firms.
Statistics reveal that in the 12 months prior to September, the UK sold medicines valued at £11.1bn to the US. This value accounted for a significant portion of total UK exports in that timeframe.
"This agreement safeguards jobs, stimulates funding and paves the way for the UK to become a international leader for life sciences," a minister remarked.
Key UK Commitments
The pact involves several notable pledges from the United Kingdom:
- Revised Affordability Limit: The UK will increase the affordability limit at which it deems new treatments to be prohibitively costly by 25%.
- Higher Drug Budget: There is a target to double total health service expenditure on medicines from 0.3 percent of Gross Domestic Product to 0.6% over the coming ten years.
- Refund Ceiling: The amount pharmaceutical firms must refund to the NHS to stay within budget will be restricted at 15%. Previously, rebates were more than 20%.
Industry Background
This agreement follows a long-running dispute between the drug companies and the British authorities over medicine costs and approval rates.
These tensions were heightened by assertions that US customers were charged several times more for the equivalent treatments than patients in the Britain and the EU.
Over the last 18 months, several significant drug company projects in the UK have been halted or cancelled, while multi-billion-dollar funding commitments have been directed toward US facilities.
A senior figure stated that the NHS must invest a greater share on drugs, noting that its budget allocation on drugs had declined as a share of its resources over the past decade.
